BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 23455400)

  • 21. A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. Gruppo Italiano Malattie Ematologiche dell'Adulto, Gruppo Italiano Trapianto di Midollo Osseo, Associazione Italiana Ematologia ed Oncologia Pediatrica, Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer and Sorveglianza Epidemiologica delle Infezioni Fungine nelle Emopatie Maligne.
    Girmenia C; Aversa F; Busca A; Candoni A; Cesaro S; Luppi M; Pagano L; Rossi G; Venditti A; Nosari AM; ; ; ; ;
    Hematol Oncol; 2013 Sep; 31(3):117-26. PubMed ID: 23037867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemo-radiotherapy. A single-center experience and review of the literature.
    Martino R; Lopez R; Sureda A; Brunet S; Domingo-Albós A
    Haematologica; 1997; 82(3):297-304. PubMed ID: 9234575
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
    Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
    J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of Antifungal Prophylaxis Drugs in Patients With Hematological Disease or Undergoing Hematopoietic Stem Cell Transplantation: A Systematic Review and Network Meta-analysis.
    Wang J; Zhou M; Xu JY; Zhou RF; Chen B; Wan Y
    JAMA Netw Open; 2020 Oct; 3(10):e2017652. PubMed ID: 33030550
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fungal colonization and invasive fungal infections following allogeneic BMT using metronidazole, ciprofloxacin and fluconazole or ciprofloxacin and fluconazole as intestinal decontamination.
    Trenschel R; Peceny R; Runde V; Elmaagacli A; Dermoumi H; Heintschel von Heinegg E; Müller KD; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2000 Nov; 26(9):993-7. PubMed ID: 11100279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A network meta-analysis of primary prophylaxis for invasive fungal infection in haematological patients.
    Leonart LP; Tonin FS; Ferreira VL; Penteado STS; Wiens A; Motta FA; Pontarolo R
    J Clin Pharm Ther; 2017 Oct; 42(5):530-538. PubMed ID: 28620958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Newer antifungal agents micafungin and voriconazole for fungal infection prevention during hematopoietic cell transplantation: a meta-analysis.
    Xu SX; Shen JL; Tang XF; Feng B; Xu HQ
    Eur Rev Med Pharmacol Sci; 2016; 20(2):381-90. PubMed ID: 26875911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifungal prophylaxis in neutropenic patients with hematologic malignancies: is there a real benefit?
    Böhme A; Karthaus M; Hoelzer D
    Chemotherapy; 1999; 45(3):224-32. PubMed ID: 10224346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis.
    Robenshtok E; Gafter-Gvili A; Goldberg E; Weinberger M; Yeshurun M; Leibovici L; Paul M
    J Clin Oncol; 2007 Dec; 25(34):5471-89. PubMed ID: 17909198
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
    Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
    Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections.
    Maschmeyer G
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i27-30. PubMed ID: 19372178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Economic evaluation of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infection in high-risk neutropenic patients in Sweden.
    Lundberg J; Höglund M; Björkholm M; Åkerborg Ö
    Clin Drug Investig; 2014 Jul; 34(7):483-9. PubMed ID: 24820968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
    Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
    Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Future role of micafungin in the treatment of invasive mycoses caused by filamentous fungi].
    Salavert-Lletí M; Zaragoza-Crespo R
    Rev Iberoam Micol; 2009 Mar; 26(1):81-9. PubMed ID: 19463284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?
    Rogers TR; Slavin MA; Donnelly JP
    Br J Haematol; 2011 Jun; 153(6):681-97. PubMed ID: 21504422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mould-active compared with fluconazole prophylaxis to prevent invasive fungal diseases in cancer patients receiving chemotherapy or haematopoietic stem-cell transplantation: a systematic review and meta-analysis of randomised controlled trials.
    Ethier MC; Science M; Beyene J; Briel M; Lehrnbecher T; Sung L
    Br J Cancer; 2012 May; 106(10):1626-37. PubMed ID: 22568999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin.
    Raad II; Hanna HA; Boktour M; Jiang Y; Torres HA; Afif C; Kontoyiannis DP; Hachem RY
    Leukemia; 2008 Mar; 22(3):496-503. PubMed ID: 18094720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Prevention of fungal infections in children and adolescents with cancer].
    Groll AH; Ritter J; Müller FM
    Klin Padiatr; 2001 Sep; 213 Suppl 1():A50-68. PubMed ID: 11577364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.